Costunolide (COS) contains a MAM structure and can alleviate pulmonary fibrosis by modulating NF-κB and TGF-β1/Smad2/Nrf2-NOX4 signaling pathways (Liu B. et al., 2019). The gene discussed is NFE2L2; the disease is pulmonary fibrosis.